Tsutomu Iwasa

Kindai University Hospital — Japan

Medicine · Health Sciences

28h-index4.0kcitations157works7.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(43), Cancer Treatment and Pharmacology(33), Advanced Breast Cancer Therapies(26), Gastric Cancer Management and Outcomes(19), Lung Cancer Research Studies(17)

Publications155 total

Effect of a self-assembling peptide hydrogel on delayed bleeding following endoscopic sphincterotomy: Prospective pilot cohort study
Endoscopy International Open·2026Open Access
Abstract PS5-01-03: Jbcrg-m06/emerald post-hoc analysis by physician’s choice of docetaxel or paclitaxel: efficacy and safety of eribulin mesylate vs taxanes combined with trastuzumab and pertuzumab as first-line for her2-positive locally advanced or metastatic breast cancer
Clinical Cancer Research·2026
Abstract PS4-01-22: The Utility of MT1-MMP in Predicting Treatment Efficacy with HER2-positive advanced or metastatic breast cancer: JBCRG-M06/EMERALD trial TR
Clinical Cancer Research·2026
Olanzapine for nausea and vomiting in people with breast cancer treated with trastuzumab deruxtecan: plain language summary of the ERICA study
Future Oncology·2025Open Access
499P Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive and HER2-negative metastatic breast cancer: Results from the phase Ⅱ AGAIN Study (WJOG14220B)
Annals of Oncology·2025Open Access
Pharmacokinetics, efficacy and safety of palbociclib and fulvestrant in a patient with hormone receptor-positive, human epidermal growth factor receptor 2 negative metastatic breast cancer with end-stage renal disease undergoing hemodialysis: A case report
Investigational New Drugs·2025· 1 citedOpen Access
Clinical and molecular landscape of metastatic extramammary Paget’s disease
The Oncologist·2025Open Access
Abstract P1-04-20: Difference in transcriptional expression and immune infiltration analysis between recurrent and de novo stage IV HER2-negative breast cancer in the NEWBEAT trial; WJOG9917BTR
Clinical Cancer Research·2025
Abstract P4-07-19: Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from NCCH1607/PATHWAY, an Asian international double-blind randomized phase 3 trial
Clinical Cancer Research·2025
Abstract 4607: Pharmacokinetic analysis of palbociclib and association with safety/efficacy in patients with HR-positive/HER2-negative advanced breast cancer: Result from PATHWAY trial
Cancer Research·2025
Spray and Forced Coagulation Mode Endoscopic Submucosal Dissection for Early Gastric Neoplasms: A Multicenter Randomized Controlled Trial
The American Journal of Gastroenterology·2025· 4 citedOpen Access
Detection of Overlooked Rare <scp><i>EGFR</i></scp> Mutations in Non‐small Cell Lung Cancer Using Multigene Testing
Thoracic Cancer·2025· 2 citedOpen Access
Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2–Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial
Journal of Clinical Oncology·2025· 8 citedOpen Access
Study protocol of an open-label prospective phase II study of Durvalumab plus Carboplatin and Etoposide in advanced large cell neuroendocrine carcinoma of the lung (LOGIK2401: NECTAR study)
Cancer Treatment and Research Communications·2025Open Access
P4.11E.24 Clinical Features of Long-Term Response (LTR) to Immune Checkpoint Inhibitors (ICIs) in Patients with Advanced or Recurrent NSCLC
Journal of Thoracic Oncology·2024Open Access
A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer
npj Breast Cancer·2024· 8 citedOpen Access
The impact of HRD mutation on survival in patients with <i>KRAS</i>-mutated advanced pancreatic cancer: A real-world database study.
Journal of Clinical Oncology·2024
Trastuzumab and pertuzumab in combination with eribulin mesylate or a taxane as first-line chemotherapeutic treatment for HER2-positive, locally advanced or metastatic breast cancer: Results of a multicenter, randomized, non-inferiority phase 3 trial in Japan (JBCRG-M06/EMERALD).
Journal of Clinical Oncology·2024· 6 cited
Abstract PO2-06-04: Prospective study on eribulin efficacy in advanced and metastatic breast cancer: changes in TGF-β compared to other standard chemotherapy agents (KBCSG-TR 2018, POTENTIAL)
Cancer Research·2024
Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade
Journal of Clinical Investigation·2024· 34 citedOpen Access
page 1 of 8Next →

Frequent Co-authors

Kazuhiko Nakagawa(23), Junji Tsurutani(14), Eikichi Ihara(12), Kazuhiko Nakamura(10), Hirotada Akiho(10), Takeshi Yoshida(9), Kazuto Nishio(8), Haruei Ogino(8), Ryoichi Takayanagi(8), Isamu Okamoto(7), Masayuki Takeda(7), Norikazu Masuda(6), Hidetoshi Hayashi(6), Kaoru Tanaka(6), Naohiko Harada(6), Yoichiro Iboshi(6), Erina Hatashita(5), Yuki Yamada(5), Masahiro Fukuoka(5), Kazuko Sakai(5)